Close Menu

Decision Biomarkers

Movers & Shakers

Premium

Glenn Barney, Dario Alessi, Philip Cohen, Stephane Bancel, Noubar Afeyan

Avantra was founded last year by Courtagen Capital Group to commercialize the assets of Decision Biomarkers, a protein biomarker technology firm that shuttered its business and filed for Chapter 7 bankruptcy in December 2009.

The company is being launched by Courtagen Capital Group using assets from defunct biotech firm Decision Biomarkers, which Courtagen purchased in bankruptcy court last December.

The demise of Perlegen Sciences and Decision Biomarkers adds two more names to a growing list of array-related firms and businesses that have gone belly up or have been shuttered in the past few years.

The company, formed in 2003, had raised at least $15.1 million in financing in its history, but in its bankruptcy filing said that its liabilities were at least 20 times that of its assets.

The Waltham, Mass.-based biomarker-detection company ceased operations and filed for Chapter 7 bankruptcy last month.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.